Jessica Burns

Ms. Jessica Burns

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
TCTom Wei-Wu Chen
Tom Wei-Wu Chen
JBJessica Burns
Jessica Burns
Robin L. JonesRobin L. Jones
Robin L. Jones
PHPaul Huang
Paul Huang
Angiosarcomas comprise less than 3% of all soft tissue sarcomas but have a poor prognosis. Most angiosarcomas occur without obvious risk factors but secondary angiosarcoma could arise after radiotherapy or chronic lymphedema. Surgery remains the standard treatment for localized angiosarcoma but neoadjuvant systemic treatment may improve the curability. For advanced angiosarcoma, anthracyclines and taxanes are the main chemotherapy options. Anti-angiogenic agents have a substantial role but the failure of a randomized phase 3 trial of pazopanib with or without an anti-endoglin antibody brings a challenge to future trials in angiosarcomas. Immune checkpoint inhibitors as single agents or in combination with oncolytic virus may play an important role but the optimal duration remains to be investigated. We also report the current understanding of the molecular pathways involved in angiosarcoma pathogenesis including MYC amplification, activation of angiogenic pathways and different molecular alterations that are associated with angiosarcomas of different aetiology. The success of the patient-partnered Angiosarcoma Project (ASCProject) has provided not only detailed insights into the molecular features of angiosarcomas of different origins but also offers a template for future fruitful collaborations between patients, physicians, and researchers. Lastly, we provide our perspective of future developments in optimizing the clinical management of angiosarcomas.

9 April 2022 in Matrix Biology
Verified
Journal Article
Open access
JHJonathan D. Humphries
Jonathan D. Humphries
JZJunzhe Zha
Junzhe Zha
JBJessica Burns
Jessica Burns
JAJanet A. Askari
Janet A. Askari
CBChristopher R. Below
Christopher R. Below
JHJon Humphries
Jon Humphries
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis due to its aggressive progression, late detection and lack of druggable driver mutations, which often combine to result in unsuitability for surgical intervention. Together with activating mutations of the small GTPase KRas, which are found in over 90% of PDAC tumours, a contributory factor for PDAC tumour progression is formation of a rigid extracellular matrix (ECM) and associated desmoplasia. This response leads to aberrant integrin signalling, and accelerated proliferation and invasion. To identify the integrin adhesion systems that operate in PDAC, we analysed a range of pancreatic ductal epithelial cell models using 2D, 3D and organoid culture systems. Proteomic analysis of isolated integrin receptor complexes from human pancreatic ductal epithelial (HPDE) cells predominantly identified integrin α6β4 and hemidesmosome components, rather than classical focal adhesion components. Electron microscopy, together with immunofluorescence, confirmed the formation of hemidesmosomes by HPDE cells, both in 2D and 3D culture systems. Similar results were obtained for the human PDAC cell line, SUIT-2. Analysis of HPDE cell secreted proteins and cell-derived matrices (CDM) demonstrated that HPDE cells secrete a range of laminin subunits and form a hemidesmosome-specific, laminin 332-enriched ECM. Expression of mutant KRas (G12V) did not affect hemidesmosome composition or formation by HPDE cells. Cell-ECM contacts formed by mouse and human PDAC organoids were also assessed by electron microscopy. Organoids generated from both the PDAC KPC mouse model and human patient-derived PDAC tissue displayed features of acinar-ductal cell polarity, and hemidesmosomes were visible proximal to prominent basement membranes. Furthermore, electron microscopy identified hemidesmosomes in normal human pancreas. Depletion of integrin β4 reduced cell proliferation in both SUIT-2 and HPDE cells, reduced the number of SUIT-2 cells in S-phase, and induced G1 cell cycle arrest, suggesting a requirement for α6β4-mediated adhesion for cell cycle progression and growth. Taken together, these data suggest that laminin-binding adhesion mechanisms in general, and hemidesmosome-mediated adhesion in particular, may be under-appreciated in the context of PDAC. Proteomic data are available via ProteomeXchange with the identifiers PXD027803, PXD027823 and PXD027827.

29 May 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
VPValeriya Pankova
Valeriya Pankova
LKLukas Krasny
Lukas Krasny
WKWilliam Kerrison
William Kerrison
YTYuen B. Tam
Yuen B. Tam
MCMadhumeeta Chadha
Madhumeeta Chadha
PHPaul Huang
Paul Huang
Purpose: The landscape of extracellular matrix (ECM) alterations in soft tissue sarcomas (STS) remains poorly characterized. We aimed to investigate the tumor ECM and adhesion signaling networks present in STS and their clinical implications. Experimental Design: Proteomic and clinical data from 321 patients across 11 histological subtypes were analyzed to define ECM and integrin adhesion networks. Subgroup analysis was performed in leiomyosarcomas (LMS), dedifferentiated liposarcomas (DDLPS), and undifferentiated pleomorphic sarcomas (UPS). Results: This analysis defined subtype-specific ECM profiles including enrichment of basement membrane proteins in LMS and ECM proteases in UPS. Across the cohort, we identified three distinct coregulated ECM networks which are associated with tumor malignancy grade and histological subtype. Comparative analysis of LMS cell line and patient proteomic data identified the lymphocyte cytosolic protein 1 cytoskeletal protein as a prognostic factor in LMS. Characterization of ECM network events in DDLPS revealed three subtypes with distinct oncogenic signaling pathways and survival outcomes. Evaluation of the DDLPS subtype with the poorest prognosis nominates ECM remodeling proteins as candidate antistromal therapeutic targets. Finally, we define a proteoglycan signature that is an independent prognostic factor for overall survival in DDLPS and UPS. Conclusions: STS comprise heterogeneous ECM signaling networks and matrix-specific features that have utility for risk stratification and therapy selection, which could in future guide precision medicine in these rare cancers.

30 October 2024
Verified
Other
Open access
VPValeriya Pankova
Valeriya Pankova
LKLukas Krasny
Lukas Krasny
WKWilliam Kerrison
William Kerrison
YTYuen B. Tam
Yuen B. Tam
MCMadhumeeta Chadha
Madhumeeta Chadha
PHPaul Huang
Paul Huang
Identification, biological and clinical characterization of DDLPS subgroups. A, Heatmap showing the supervised clustering of 57 differentially expressed matrisome and adhesome proteins (DEPs) uniquely upregulated in each DDLPS subgroup. Black boxes indicate unique upregulated matrisome and adhesome DEPs in each of the subgroups. Bottom annotations indicate key tumor and patient characteristics. “*” Indicates that a clinical feature is significantly associated with DDLPS subgroups. B, Identities of upregulated matrisome and adhesome proteins in each DDLPS subgroup are shown on the right. Colored boxes on the right show functional pathways enriched in each DDLPS subgroup, as determined by overrepresentation analysis against the reactome pathway database. (C) Stacked bar charts showing the percentages of high and low CD3+, CD4+, and CD8+ TIL groups in each DDLPS subgroup. DDLPS cases were divided into high and low categories according to the median TILs score, separately for each stain. The χ2 test results are presented at the top of each plot. D, Significant (one-way ANOVA; FDR < 0.05) biological features obtained from ssGSEA of the MSigDB Hallmark gene sets. E, Kaplan–Meier plot of LRFS with stratification by DDLPS subgroups. Hazard ratio, 95% CI, and P-values were determined by univariate Cox regression with a two-sided Wald test.

30 October 2024
Verified
Other
Open access
VPValeriya Pankova
Valeriya Pankova
LKLukas Krasny
Lukas Krasny
WKWilliam Kerrison
William Kerrison
YTYuen B. Tam
Yuen B. Tam
MCMadhumeeta Chadha
Madhumeeta Chadha
PHPaul Huang
Paul Huang
Matrisome and adhesome networks in STS. A, Heatmap showing a similarity matrix of Pearson’s correlation coefficients for all pairwise comparisons of matrisome and adhesome proteins. Heatmap is split into three clusters (C1, C2, and C3) identified by consensus clustering analysis. B, Pie charts showing breakdown of proteins within the clusters into adhesome, core matrisome, or matrisome-associated proteins (top), breakdown by matrisome class (middle) and by functional annotation of adhesome (bottom). C, Selected protein–protein interaction networks (colored by clusters) are shown for each cluster as identified by enrichment analysis (reactome pathways). D, Box plots showing distributions of median expression of C1, C2 and C3 proteins across tumor grades. Boxes indicate 25th and 75th percentile, with the median line in the middle, whiskers extending from 25th percentile − [1.5 × interquartile range (IQR)] to 75th percentile + (1.5 × IQR), and outliers plotted as points. Significance determined by Mann–Whitney U test. ***, P < 0.001; ****, P < 0.0001. E, Box plots showing distributions of median expression of C1, C2 and C3 proteins across histological subtypes. Boxes indicate 25th and 75th percentile, with the median line in the middle, whiskers extending from 25th percentile − (1.5 × IQR) to 75th percentile + (1.5 × IQR), and outliers plotted as points. Significance determined by Kruskal–Wallis tests with Dunn’s multiple corrections tests. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. Other, ASPS, alveolar soft part sarcoma; CCS, clear cell sarcoma; DSRCT, desmoplastic small round cell tumor; ES, epithelioid sarcoma; RT, rhabdoid tumor.